GWM
ATOS icon

Geneos Wealth Management’s Atossa Therapeutics ATOS Stock Holding History

Geneos Wealth Management’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-67
Closed -$1K – 2036
2022
Q2 		$1K Hold
67
– – ﹤0.01% 2464
2022
Q1 		$1K Hold
67
– – ﹤0.01% 2610
2021
Q4 		$1K Hold
67
– – ﹤0.01% 2643
2021
Q3 		$3K Sell
67
-200
-75% -$11.6K ﹤0.01% 2555
2021
Q2 		$21K Buy
267
+67
+34% +$3.55K ﹤0.01% 1888
2021
Q1 		$6K Hold
200
– – ﹤0.01% 2577
2020
Q4 		$6K Buy
+200
New +$4.63K ﹤0.01% 2399

Other funds holding ATOS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

Geneos Wealth Management's ATOS Position: Q3 2022 in Review

Geneos Wealth Management sold out of Atossa Therapeutics (ATOS) in Q3 2022, closing a stake of 67 shares — an estimated $1K sold.

Geneos Wealth Management first reported a position in ATOS in Q4 2020 and held it in 7 quarters. The position peaked at $21K in Q2 2021. 56 funds tracked by Wall St. Rank hold ATOS as of Q3 2022.

  • Geneos Wealth Management reported no remaining Atossa Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Geneos Wealth Management sold 67 Atossa Therapeutics shares in Q3 2022, an estimated $1K.
  • Geneos Wealth Management first reported a position in Atossa Therapeutics in Q4 2020 and held it in 7 quarters.
  • Geneos Wealth Management's Atossa Therapeutics position peaked at $21K in Q2 2021.
  • 56 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q3 2022.

Based on Geneos Wealth Management's 13F filing for Q3 2022, filed 14 Nov 2022.